Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

Polls provide a useful window into understanding how Americans view their own weight and the recent availability of drugs ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

To accomplish these goals, it's fair to assume that some people will ultimately turn to weight-loss drugs such as Ozempic and ...

The amount of health care Minnesotans got in 2022 didn’t grow much from the year before — but the amount they paid for it ...

If the drug is currently prescribed for another purpose, DSS said it would no longer cover the cost after Jan. 15. Now, Medicaid enrollees who use GLP-1 agonists for weight loss won’t have many ...

Wegovy was approved by the FDA in 2021, after showing it helped ... ‘Novo Nordisk is going to have a new drug [where] 40% of people will get 25% weight loss, but that’ll be pretty ...

“Among adults, 5.4% of all prescriptions in September 2024 were for GLP-1s,” Rodriguez says. That is up from 3.5% a year earlier, in 2023, and 1% at the start of 2021.

NEW YORK (Reuters) -U.S. healthcare spending rose by 7.5% to $4.9 trillion in 2023, driven by increased use of medical ...

18 (UPI) --Merck announced a weight loss drug deal Wednesday ... an experimental oral GLP-1 drug made by China-based Eccogene. France confirms first case of new mpox strain Jan. 7 (UPI) -- French ...